Papillary thyroid cancer medical therapy

Jump to: navigation, search

Papillary thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Papillary thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Papillary thyroid cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Papillary thyroid cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Papillary thyroid cancer medical therapy

CDC on Papillary thyroid cancer medical therapy

Papillary thyroid cancer medical therapy in the news

Blogs on Papillary thyroid cancer medical therapy

Directions to Hospitals Treating Papillary thyroid cancer

Risk calculators and risk factors for Papillary thyroid cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Ammu Susheela, M.D. [3]

Overview

Treatment options for papillary thyroid cancer differes according to the stage and invasion of the tumor and include surgery, external beam radiation therapy ( EBRT), Thyroid suppression therapy, and targeted therapy.

Medical Therapy

  • Treatment options for papillary thyroid cancer include:[1]
 
 
 
 
 
 
 
 
Papillary thyroid cnacer treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Localized or regional tumor
 
 
 
 
Metastatic
 
 
 
 
Recurrent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgery
Total thyroidectomy
Lobectomy
RAI therapy
Thyroid suppression therapy
EBRT
 
 
 
 
 
 
 
 
 
 
 
 
Surgery ± postoperative RAI therapy
Targeted therapy
EBRT
Chemotherapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Iodine sensitive
 
 
 
Iodine resistent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RAI therapy
Thyroid suppression therapy
 
 
 
Thyroid suppression therapy
Targeted therapy
Surgery
EBRT
 
Papillary Thyroid Cancer Treatment Options
  • Pharmacologic medical therapies for papillary thyroid cancer include thyroid-suppression therapy, and/or targeted therapy.

Thyroid-suppression therapy

Targeted therapy

  • This type of treatment is done using:[2][3]
    • Sorafenib, an Sorafenib is an orally active, multityrosine kinase inhibitor.
    • Lenvatinib, an orally active, multitargeted tyrosine kinase inhibitor.[4]
      • Adult
        • Preferred regimen: Lenvatinib 24 mg PO daily until disease progression or unacceptable toxicity.
        • Alternative regimen: Sorefenib 400 mg PO q12h until disease progression or unacceptable toxicity.
        • Alternative regimen: Larotrectinib 100 mg PO q12h until disease progression or unacceptable toxicity.
        • Alternative regimen: Entrectinib 600 mg PO daily until disease progression or unacceptable toxicity.

References

  1. "Thyroid Cancer Treatment (Adult) (PDQ®)–Health Professional Version - National Cancer Institute".
  2. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL (January 2013). "The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring". J. Clin. Endocrinol. Metab. 98 (1): 31–42. doi:10.1210/jc.2012-2909. PMC 3537108. PMID 23185034.
  3. Cabanillas ME, Hu MI, Durand JB, Busaidy NL (2011). "Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer". J Thyroid Res. 2011: 985780. doi:10.4061/2011/985780. PMC 3189619. PMID 22007339.
  4. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (February 2015). "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer". N. Engl. J. Med. 372 (7): 621–30. doi:10.1056/NEJMoa1406470. PMID 25671254.



Linked-in.jpg